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TO THE EDITOR
Pemphigus vulgaris (PV) is an autoim-
mune disease characterized by epider-
mal blistering involving mucosa or
mucosa and skin (Ding et al., 1997).
In PV, autoantibodies directed against
the desmosome cadherins desmoglein
(dsg) 3 and dsg1 induce loss of cell–cell
adhesion (acantholysis) resulting in
clinical blisters. Passive transfer experi-
ments using IgG, purified from PV
patients (Anhalt et al., 1982) or highly
specific anti-dsg3 monoclonal antibo-
dies (Tsunoda et al., 2003; Payne et al.,
2005), reproduce the clinical, histolo-
gic, and immunologic features of PV in
the infused animals. Similarly, pemphi-
gus foliaceus (PF) is an autoimmune
blistering disease of the skin in which
autoantibodies to dsg1 cause acantho-
lysis in the subcorneal and granular
layers of the epidermis. IgG purified
from PF patient sera similarly repro-
duces disease in the passive transfer
mouse model (Roscoe et al., 1985;
Rock et al., 1989).
We and others have been studying
the molecular mechanism by which
anti-dsg autoantibodies cause acantho-
lysis in pemphigus. Using keratinocyte
tissue culture and murine in vivo
models, we have demonstrated that
anti-dsg3 PV IgG induce rapid, time-
and dose-dependent phosphorylation of
p38 mitogen-activated protein kinase
(MAPK) and heat shock protein 27
(HSP27) (Berkowitz et al., 2005). Acti-
vation of keratinocyte p38MAPK and
HSP27 by PV IgG may be relevant to
the mechanism of acantholysis in PV
since (i) both p38MAPK and HSP27
regulate components of the cytoskele-
ton including actin and intermediate
filaments (Lavoie et al., 1993, 1995;
Benndorf et al., 1994; Guay et al.,
1997; Perng et al., 1999; Geum et al.,
2002; Panasenko et al., 2003; Evgrafov
et al., 2004) and (ii) in human kerati-
nocyte cultures, inhibitors of p38MAPK
prevented PV IgG-induced phosphory-
lation of HSP27 and the early cytoske-
letal changes associated with the loss of
cell–cell adhesion (Berkowitz et al.,
2005). These observations suggested
that inhibition of this signaling pathway
in epidermal epithelia could be used to
prevent end-organ damage (e.g. blister-
ing) caused by PV autoantibodies.
Indeed, in the PV passive transfer
mouse model we found that (i)
p38MAPK and HSP25, the murine
HSP27 homolog, are similarly phos-
phorylated in vivo, and significantly (ii)
p38MAPK inhibitors block blister for-
mation in this vivo model of PV
(Berkowitz et al., 2006). These observa-
tions in tissue culture and animal
models suggest a central role for
p38MAPK and HSP27 in the mechan-
isms of acantholysis in PV. Importantly,
targeting this signaling pathway with
inhibitors may have a role in treating
patients with pemphigus; however, we
have yet to determine whether
p38MAPK and HSP27 are similarly
phosphorylated in lesional epidermis
of pemphigus patients.
In this study, we probe for phosphor-
ylation of p38MAPK and HSP27 in skin
biopsies of one PF and five PV patients
and six specimens from control indivi-
duals affected by other skin diseases;
this study was approved by the Institu-
tional Review Board at UNC. A diag-
nosis of PV or PF was established by
clinical, histological, and immunologi-
cal criteria (Diaz and Giudice, 2000).
The clinical and serological features of
the six patients are shown in Table 1.
Biopsies from control individuals
showed no immunoreactants by direct
immunofluorescence or histologic signs
of pemphigus.
Extracts were made from frozen
archived perilesional skin biopsies in
8 M urea buffer (8 M urea, 4% CHAPS,
10 mM pepstatin, 100mM leupeptin,
10 mM E-64, 1mM PMSF, 1mM Na3VO4,
50mM NaF, 0.5 mM okadaic acid). Pro-
tein concentration was determined by
Bradford method as described pre-
viously (Berkowitz et al., 2005). Tissue
extracts were separated by 10% SDS-
PAGE and immunoblotted using mono-
clonal antibodies against p38MAPK
(Santa Cruz Biotechnology Inc., Santa
Cruz, CA), phospho-p38MAPK (Cell
Signaling Technology, Beverly, MA),
HSP27 (ABR, Golden, CO), and phos-
pho-HSP27 (Cell Signaling Technol-
ogy). Western blots were developed
by ECL reaction and the signal intensity
quantified by scanning chemilumines-
cence on a GeneGnome scanner (Syn-
gene Bio Imaging, Frederick,MD) using
GeneSnap software. Compared to con-
trols, increased phosphorylation of
p38MAPK was observed in 1 PF and 3
of the 5 PV skin biopsies; whereas,
increased HSP27 phosphorylation was
observed in all PF and PV patient skin
biopsies (Figure 1). In our earlier work
with in vivo mouse models, we have
noted degradation in the phospho-
p38MAPK signal with extended sample
storage time even at 701C, this ex-
plains the discrepancy between the
phospho-p38MAPK and phospho-
HSP27 signals observed in 2 of the 5
PV skin biopsies (PV4 and PV5). In-
creased phosphorylation of p38MAPK
and HSP27 was observed in both muco-
sal and mucocutaneous variants of PV.
The observed activation of intra-
cellular signaling events mediated by
p38MAPK and HSP27 in patient skin is
analogous to the increased phosphory-
lation of these two proteins that we
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have previously reported in human
keratinocyte tissue culture and in vivo
mouse models. Importantly, a number
of p38MAPK inhibitors are currently in
early-phase clinical trials for inflamma-
tory and neoplastic diseases (O’Neill,
2006). Along with the earlier in vitro
and in vivo mouse model studies, the
observation that p38MAPK and HSP27
are phosphorylated in biopsies from
perilesional skin of human pemphigus
patients provides additional evidence to
support the notion that p38MAPK in-
hibitors may be applicable to the
therapy of patients suffering from the
pemphigus family of autoimmune blis-
tering diseases.
CONFLICT OF INTEREST
Paula Berkowitz, Luis A. Diaz, and David S.
Rubenstein are co-inventors on a patent identifying
p38MAPK and HSP27 as targets for the treatment
of pemphigus. Neither licensing agreements nor
financial benefit has accrued to the inventors.
ACKNOWLEDGMENTS
This work was supported by the National Institutes
of Health Grants RO1 AI49427 (to D.S.R.), and
AR30281, AR32599 (to L.A.D.).
Paula Berkowitz1, Luis A. Diaz1, Russell
P. Hall2 and David S. Rubenstein1,3
1Department of Dermatology, University of
North Carolina, Chapel Hill, North Carolina,
USA; 2Dermatology Division, Duke University
Medical Center, Durham, North Carolina, USA
and 3Lineberger Comprehensive Cancer
Center, University of North Carolina, Chapel
Hill, North Carolina, USA
E-mail: druben@med.unc.edu
REFERENCES
Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA
(1982) Induction of pemphigus in neonatal
mice by passive transfer of IgG from patients
with the disease. N Engl J Med 306:1189–96
Benndorf R, Hayess K, Ryazantsev S, Wieske M,
Behlke J, Lutsch G (1994) Phosphorylation
and supramolecular organization of murine
small heat shock protein HSP25 abolish its
actin polymerization-inhibiting activity.
J Biol Chem 269:20780–4
Berkowitz P, Hu P, Liu Z, Diaz LA, Enghild JJ,
Chua MP et al. (2005) Desmosome signaling:
inhibition of p38MAPK prevents pemphigus
vulgaris IgG-induced cytoskeleton reorgani-
zation. J Biol Chem 280:23778–84
Berkowitz P, Hu P, Warren S, Liu Z, Diaz LA,
Rubenstein DS (2006) p38MAPK inhibition
prevents disease in pemphigus vulgaris mice.
Proc Natl Acad Sci USA 103:12855–60
Diaz LA, Giudice GJ (2000) End of the century
overview of skin blisters. Arch Dermatol
136:106–12
Ding X, Aoki V, Mascaro JM Jr, Lopez-Swiderski
A, Diaz LA, Fairley JA (1997) Mucosal and
mucocutaneous (generalized) pemphigus
vulgaris show distinct autoantibody profiles.
J Invest Dermatol 109:592–6
Evgrafov OV, Mersiyanova I, Irobi J, Van Den Bosch
L, Dierick I, Leung CL et al. (2004) Mutant
small heat-shock protein 27 causes axonal
Charcot–Marie–Tooth disease and distal her-
editary motor neuropathy.Nat Genet 36:602–6
Geum D, Son GH, Kim K (2002) Phosphorylation-
dependent cellular localization and thermo-
protective role of heat shock protein 25 in
hippocampal progenitor cells. J Biol Chem
277:19913–21
Guay J, Lambert H, Gingras-Breton G, Lavoie JN,
Huot J, Landry J (1997) Regulation of actin
filament dynamics by p38 map kinase-
mediated phosphorylation of heat shock
protein 27. J Cell Sci 110:357–68
Lavoie JN, Hickey E, Weber LA, Landry J (1993)
Modulation of actin microfilament dynamics
and fluid phase pinocytosis by phosphoryla-
tion of heat shock protein 27. J Biol Chem
268:24210–4
Lavoie JN, Lambert H, Hickey E, Weber LA,
Landry J (1995) Modulation of cellular
thermoresistance and actin filament stabi-
lity accompanies phosphorylation-induced
changes in the oligomeric structure of heat
shock protein 27. Mol Cell Biol 15:505–16
O’Neill LA (2006) Targeting signal transduction as
a strategy to treat inflammatory diseases. Nat
Rev Drug Discov 5:549–63
Table 1. Clinical and immunologic characteristics of patients from which
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Cases Phenotype IIF titer Dsg1-ELISA Dsg3-ELISA
PF PF 1:10,240 Positive Negative
PV1 mcPV 1:40 Positive Positive
PV2 mcPV 1:640 Positive Positive
PV3 mPV 1:320 Negative Positive
PV4 mcPV 1:1,280 Positive Positive
PV5 mcPV 1:160 Positive Positive
Dsg, desmoglein; IIF, indirect immunofluorescence; PF, pemphigus foliaceus, PV, pemphigus
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Figure 1. Increased phospho-p38MAPK and phospho-HSP27 in human pemphigus skin biopsies.
(a) Extracts from a PF patient (PF), 5 PV patients (PV1–5), and control (C1–6) human skin biopsies were
separated by 10% SDS-PAGE and probed by immunoblot with antibodies to phosphorylated p38MAPK
(phos-p38), total p38MAPK (p38), phosphorylated HSP27 (phos-HSP27), and total HSP27.
(b) Quantitation of p38 immunoblots; phosphorylated p38MAPK expressed as ratio of phospho-p38MAPK
to total p38MAPK. Mean values for pemphigus (Pem) samples and controls (CON) are shown. Error bars
show SD. Statistical significance determined by Mann–Whitney test; *P-value¼0.025. (c) Quantitation of
HSP27 immunoblots; phosphorylated HSP27 expressed as ratio of phospho-HSP27 to total HSP27. Mean
values for pemphigus (Pem) samples and controls (CON) are shown. Error bars show SD. Statistical
significance determined by Mann–Whitney test; **P-value¼ 0.037.
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TO THE EDITOR
In vivo confocal laser scanning micro-
scopy (CLSM) is a tool for obtaining
‘‘optical biopsies’’ of skin lesions at
near histological resolution. Earlier in-
vestigations have suggested that this
instrument may be useful as a surgical
guide for the controlled excisions of
cutaneous tumors and may be espe-
cially useful for lesions with poorly
defined borders (e.g., lentigo maligna
melanomas). In vivo CLSM for the
microsurgery of basal cell carcinoma
(Tannous et al., 2003; Marra et al.,
2005) and malignant melanoma (Curiel-
Lewandrowski et al., 2004; Chen et al.,
2005) have been reported.
Currently, in vivo CLSM has been
used in the reflectance mode. Tumor
detection is based on differences in the
refractive indices between normal and
malignant tissues. However, exogenous
contrast reagents may increase the de-
tail of lesions for the demarcation of
tumor margins. For example, Tannous
et al. (2003) reported that aluminum
chloride minimized the mismatch be-
tween the tissue and immersion med-
ium refractive indices and improved the
identification of basal cell carcinoma
tumor margins in patients undergoing
Mohs micrographic surgery.
In vivo CLSM can also be used in the
fluorescence mode (Li et al., 2005).
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Figure 1. Pharmacokinetics and biodistributions of radiolabeled TRITC peptide conjugates. (a) [125I]
TRITC-Pep-1 (red circles) and the [125I]TRITC-scrambled control (black circles) were intravenously injected
into tumor-bearing C57BL/6 mice (0.02mgkg1) and serially bled at the indicated time points. Blood
samples were measured in a g-counter, and the results were expressed as the % of injected dose per ml
(%IDml1). Results are expressed as the means7SD of three mice per group. Differences between TRITC-
Pep-1 and the TRITC-scrambled control were not significant by the two-tailed Mann–Whitney U-test
(P40.05). (b) Non-compartmental pharmacokinetic parameters for TRITC-Pep-1 (red bars) and the TRITC-
scrambled control (black bars) were estimated from the curves shown in (a) using WinNonlin software.
Abbreviations for the derived pharmacokinetic parameters are volume of distribution at steady state (Vss),
clearance (CL) and mean residence time (MRT). Values are expressed as the means7SD. Differences in the
derived pharmacokinetic parameters between TRITC-Pep-1 and the TRITC-scrambled control were not
significant by the two-tailed Mann–Whitney U-test (P40.05). (c) [125I]TRITC-Pep-1 (red bars) and the
[125I]TRITC-scrambled control (black bars) were intravenously injected into tumor-bearing C57BL/6 mice
(0.02mgkg1) and killed 16hours later. The radioactivities of tissues were measured in a g-counter after
first measuring the organ weights. Results shown are the means7SD of three mice per group and significant
differences determined using the two-tailed Mann–Whitney U-test (*Po0.05).
Abbreviations: CLSM, confocal laser scanning microscopy; GFP, green fluorescent protein
HA, hyauronan; TRITC, tetramethylrhodamine isothiocyanate
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